Alterity Therapeutics Announced Presentation Of New Data Demonstrating Potential Of ATH434 To Treat Rare Neurodegenerative Disease Friedreich's Ataxia
Alterity Therapeutics Announced Presentation Of New Data Demonstrating Potential Of ATH434 To Treat Rare Neurodegenerative Disease Friedreich's Ataxia
Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that important new data on its lead drug candidate ATH434 was presented at the World Orphan Drug Congress USA 2024 in Boston, MA. The poster, entitled, "Biophysical Characteristics of ATH434, a Unique Iron-Targeting Drug for Treating Friedreich's Ataxia", was presented by Ashley Pall, Department of Pharmaceutical Sciences at Wayne State University. The study evaluated the ability of ATH434 to target the toxic form of iron that drives the pathology of Friedreich's Ataxia, a rare neurodegenerative disease that affects young children to young adults. The study also evaluated traditional iron chelators that are designed to bind iron and remove iron from the body. Conversely, an iron chaperone is designed to bind and redistribute iron within the bod
致力于开发神经退行性疾病改良疗法的生物技术公司Alterity Therapeutics（（澳大利亚证券交易所股票代码：ATH，纳斯达克股票代码：ATH）（“Alterity” 或 “公司”）今天宣布，其主要候选药物 ATH434 的重要新数据已在马萨诸塞州波士顿举行的2024年美国世界孤儿药大会上公布。这张海报名为 “用于治疗弗里德赖希共济失调的独特铁靶向药物 ATH434 的生物物理特性”，由韦恩州立大学药物科学系的阿什利·帕尔主持。该研究评估了 ATH434 靶向导致弗里德赖希共济失调病理的有毒铁的能力，弗里德赖希共济失调是一种罕见的神经退行性疾病，会影响幼儿到年轻人。该研究还评估了旨在结合铁和去除体内铁的传统铁螯合剂。相反，铁监护人旨在绑定和重新分配体内铁质